Royalty Pharma dividend and valuation
Valuation
Royalty Pharma paid $0.94 per share in dividends over the last 12 months (yield 1.4%). Last ex-dividend date: November 13, 2026. The P/E ratio is 45.3. The average price target of 8 analysts is $72.00.
What would Royalty Pharma's dividends pay over 10 years? Work it out with the dividend calculator
Data as of November 16, 2026
Royalty Pharma compared with similar companies
Royalty Pharma's P/E (trailing 12 months): 45.3, +15% against the median of a group of 6 similar companies (39.3).
| Metric | Royalty Pharma | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 45.3 | 39.3 | 21.9 – 51.4 | Middle |
| Forward P/E | 11.7 | 22.9 | 14.6 – 33.8 | Low |
| EV/EBITDA | 24.8 | 24.8 | 20.8 – 33.0 | Middle |
| Price/book | 4.52 | 8.17 | 5.33 – 14.4 | Low |
| Price/sales | 15.2 | 12.6 | 7.59 – 16.9 | Middle |
| Gross margin | 99.8% | 76.7% | 28.0% – 86.9% | High |
| Operating margin | 64.4% | 17.8% | -68.1% – 31.4% | High |
| Net margin | 25.7% | 6.7% | -19.9% – 28.7% | Middle |
| ROE | 12.1% | 7.8% | -21.5% – 21.0% | Middle |
| Debt/equity | 0.88 | 0.35 | 0.02 – 0.73 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Royalty Pharma: valuation over time
On the latest fiscal year's earnings (2025), Royalty Pharma's P/E today is 38.6, above the median of its last 5 fiscal years (21.7; between 11.1 and 37.9 from 2020 to 2025). Relative to earnings, the stock costs more than it used to. The dividend yield (1.4%) is below the median of the last 6 fiscal years (2.1%).
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| 2025 | $38.64 | $1.78 | 21.7 | $0.88 | 2.3% |
| 2024 | $25.51 | $1.91 | 13.3 | $0.84 | 3.3% |
| 2023 | $28.09 | $2.53 | 11.1 | $0.80 | 2.8% |
| 2022 | $39.52 | $0.10 | — | $0.76 | 1.9% |
| 2021 | $39.85 | $1.49 | 26.7 | $0.68 | 1.7% |
| 2020 | $50.05 | $1.32 | 37.9 | $0.30 | 0.6% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $39.85B
- Enterprise value
- $41.86B
- PEG
- 2.10
- EV/revenue
- 16.0
Profitability and growth
- ROA
- 5.4%
- ROIC
- 5.3%
- Revenue growth (year over year)
- 13.3%
- Earnings growth (year over year)
- -50.8%
Financial health
- Total cash
- $544.86M
- Total debt
- $8.59B
- Current ratio
- 1.29
- Quick ratio
- 1.29
- Altman Z-Score
- 1.93
- Piotroski F-Score
- 6.00
Dividends
- Annual dividend per share
- $0.94
- Dividend yield
- 1.4%
- Payout ratio
- 61.4%
- Ex-dividend date
- November 13, 2026
Analysts and estimates
- Average price target
- $72.00
- Median price target
- $74.00
- High price target
- $78.00
- Low price target
- $66.00
- Analysts with a price target
- 8
- Consensus
- Buy
- Forward EPS
- $5.91
- EPS estimate, current year
- $5.39
Shares and trading
- Beta
- 0.36
- Average volume
- 3.17M
- Shares outstanding
- 445.27M
- Float
- 417.1M
- Institutional ownership
- 88.1%
- Insider ownership
- 6.9%
- Short interest (% of float)
- 3.0%
- Short ratio (days)
- 4.05
